Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Momenta Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Momenta Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Momenta Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Momenta Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Momenta Pharmaceuticals, Inc.'s pipeline products Reason to Buy - Evaluate Momenta Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Momenta Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Momenta Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Momenta Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Momenta Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Momenta Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Momenta Pharmaceuticals, Inc. Snapshot 5 Momenta Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Momenta Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Momenta Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Momenta Pharmaceuticals, Inc. - Pipeline Products Glance 10 Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products 11 IND/CTA Filed Products/Combination Treatment Modalities 11 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Momenta Pharmaceuticals, Inc. - Drug Profiles 14 necuparanib 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 adalimumab biosimilar 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 abatacept biosimilar 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Antibody for Autoimmune Disorders and Inflammation 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Recombinant Protein to Antagonize F3 Receptor for Autoimmune Disorders 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Antibodies for Autoimmune Diseases 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 M-597 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 M-615 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 M-706 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Momenta Pharmaceuticals, Inc. - Pipeline Analysis 23 Momenta Pharmaceuticals, Inc. - Pipeline Products by Target 23 Momenta Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 24 Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 25 Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 26 Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates 27 Momenta Pharmaceuticals, Inc. - Dormant Projects 29 Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products 30 Discontinued Pipeline Product Profiles 30 M-511 30 Momenta Pharmaceuticals, Inc. - Company Statement 31 Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries 35 Head Office 35 Other Locations & Subsidiaries 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Momenta Pharmaceuticals, Inc., Key Information 5 Momenta Pharmaceuticals, Inc., Key Facts 5 Momenta Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7 Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8 Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9 Momenta Pharmaceuticals, Inc. - Phase II, 2015 10 Momenta Pharmaceuticals, Inc. - IND/CTA Filed, 2015 11 Momenta Pharmaceuticals, Inc. - Preclinical, 2015 12 Momenta Pharmaceuticals, Inc. - Discovery, 2015 13 Momenta Pharmaceuticals, Inc. - Pipeline by Target, 2015 23 Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 24 Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 25 Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 26 Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 27 Momenta Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 29 Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 30 Momenta Pharmaceuticals, Inc., Subsidiaries 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.